预约演示
更新于：2025-08-17
Mepivacaine Hydrochloride
盐酸甲哌卡因
更新于：2025-08-17
概要
基本信息
原研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 (1956-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C15H23ClN2O |
InChIKeyRETIMRUQNCDCQB-UHFFFAOYSA-N |
CAS号1722-62-9 |
关联
80
项与 盐酸甲哌卡因 相关的临床试验NCT06927726
Assessment of Anesthetic Efficacy and Hemodynamic Stability of 4% Articaine (1:100,000 Epinephrine) Versus 3% Mepivacaine Used in Maxillary Teeth Extraction for Hypertensive Patients: A Double-blind Randomized Clinical Study
NCT06271174
Impact Evaluation of Perioperative Locoregional Analgesia on Persistent Postoperative Pain in Children After Orthopedic Surgery for Traumatology : a Prospective, Single Center, Randomised Controlled Study.
NCT05425979
Onset of Sensory Blockade in Ultrasound-Guided Ankle Block With Mepivacaine Versus Bupivacaine: A Randomized Non-Inferiority Clinical Trial
100 项与 盐酸甲哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸甲哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸甲哌卡因 相关的专利（医药）
登录后查看更多信息
2,570
项与 盐酸甲哌卡因 相关的文献（医药）2025-07-03Pain Management
Efficacy of intra-articular opioid injections for managing temporomandibular joint nociception: a systematic review
Review
作者: Rossouw, P. Emile ; Javed, Fawad ; Bhide, Madhuli
AIM:
This systematic review evaluated randomized controlled trials (RCTs) investigating the effectiveness of intra-articular opioid injections for managing temporomandibular joint (TMJ) pain.
METHODS:
A comprehensive search of indexed databases and Google Scholar was conducted following PRISMA guidelines. Included studies assessed self-reported TMJ pain and maximum mouth opening (MMO) as primary and secondary outcomes, respectively. Risk of bias (RoB) was evaluated using the Cochrane tool, and evidence certainty was rated using the GRADE framework.
RESULTS:
Ten RCTs met the inclusion criteria, with follow-up periods ranging from 30 minutes to 6 months. Six trials demonstrated significant pain reduction after opioid injections, while one reported no difference following morphine use. Another study found mepivacaine more effective than morphine or saline. Regarding MMO, one trial showed no effect of morphine, whereas two trials found that 1 mg morphine or 1 ml buprenorphine led to greater improvements than 0.1 mg morphine. In three trials, opioids enhanced MMO more than sodium hyaluronate. All studies exhibited low RoB. Certainty of evidence was moderate in six RCTs and low in three.
CONCLUSION:
There is no credible evidence for the benefit of intra-articular opioid-injections for managing TMJ nociception.
PROTOCOL REGISTRATION:
www.crd.tork.ac.uk/prospero identified is CRD42024598035.
2025-07-01AMERICAN JOURNAL OF VETERINARY RESEARCH
Euthanasia of canines and felines under anesthesia can be achieved with lidocaine or mepivacaine via intrathecal, intravenous, or intracardiac routes
Article
作者: Robertson, Sheilah A. ; Cooney, Kathleen A. ; Kogan, Lori R.
Abstract:
Objective:
To determine the effectiveness of lidocaine (L) and mepivacaine (M) as euthanasia agents in canine and feline patients via intrathecal (ITh), intravenous (IV), and intracardiac (IC) routes following induction of general anesthesia.
Methods:
Canine and feline patients were euthanized from April 2024 through September 2024 at an animal shelter. Patients were randomly selected as part of an experimental study to receive L or M into the spinal subarachnoid space (ITh) or by IV or IC injection. Time to death and active signs of dying were recorded.
Results:
A total of 54 canines and 66 felines were euthanized. Canines: mean time (± SD) to death (cardiac standstill) from ITh administration was 313.0 ± 74.4 seconds (L) and 261.4 ± 28.9 seconds (M); mean time to death from IV or IC administration was 203.8 ± 77.6 seconds (L) and 212.5 ± 37.8 seconds (M). Felines: mean time to death from ITh administration was 245.8 ± 65.0 seconds (L) and 311.0 ± 100.4 seconds (M); mean time to death after IV or IC administration was 98.9 ± 58.8 seconds (L) and 123.2 ± 86.6 seconds (M).
Conclusions:
L and M cause death in anesthetized canine and feline patients when administered at lethal doses (4 mg/kg ITh and 28 mg/kg, IV or IC). The ITh route took longer to achieve death in both species but had reduced active signs of death.
Clinical Relevance:
L and M may be used as alternative euthanasia agents when pentobarbital sodium is unavailable or undesired.
2025-07-01JOURNAL OF ARTHROPLASTY
Outcomes of Low-Dose 2% Mepivacaine Spinal for Total Hip and Knee Arthroplasty in an Ambulatory Surgery Center Setting
Article
作者: Schwab, Joseph M ; Gresham, Natalie L ; Bradbury, Thomas L ; McConnell, Mary Jane ; Bradham, Anita Alex
BACKGROUND:
Optimizing anesthetic duration enhances recovery and efficiency in total joint arthroplasty (TJA). Spinal anesthesia with 2% mepivacaine offers a rapid onset and shorter duration, but optimal dosing strategies remain unclear. We examined (1) the relationship between time to motor function recovery and dose of 2% mepivacaine, (2) procedure- and patient-specific factors associated with differences in motor function recovery and postoperative pain, and (3) the incidence of transient neurological symptoms (TNS), postoperative urinary retention (POUR), and other side effects at various doses.
METHODS:
This prospective observational study enrolled 212 patients undergoing primary TJA at a single ambulatory surgery center between September 2024 and January 2025. The mepivacaine dose was based on anticipated surgical duration, not on height and weight. The primary outcome, time to motor function recovery (defined as initiation of spinal anesthesia to achievement of Bromage 0),was assessed every 10 minutes upon arrival in the post-anesthesia care unit (PACU). Secondary outcome measures included the incidence of POUR, TNS, pain scores, perioperative durations, milestone achievement, drug administration, and adverse anesthesia effects.
RESULTS:
There was a strong positive correlation between dose and motor recovery time (R2 = 0.954, P<0.001). Higher doses (1.7 mL) resulted in longer recovery times (99.8 ± 19.4 minutes) than lower doses (1.0 mL, 60.1 ± 7.2 minutes). Multivariate stepwise linear regression analyses revealed that age (β = 0.29, P = 0.011) and weight (β = -0.07, P = 0.007) were significantly associated with recovery time. The NRS pain at discharge was not associated with dose (P = 0.934) or spinal level (P = 0.620). There were no POUR and three cases of TNS were observed.
CONCLUSION:
Basing the spinal mepivacaine dose on anticipated surgical time, rather than solely on demographic factors, appears to be safe and effective in optimizing motor function recovery without increasing adverse events.
100 项与 盐酸甲哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | - | - | 1956-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 神经阻滞 | 临床2期 | 中国 | 2012-07-10 | |
| 臂丛神经病 | 临床1期 | 中国 | - | |
| 糖尿病性神经病变 | 临床前 | 美国 | - | |
| 疱疹后神经痛 | 临床前 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 40 | 願糧醖獵網願鹽獵鹹繭(鹽廠憲鹹廠淵糧鑰觸鹽) = 醖醖網衊窪選鏇遞衊齋 鑰窪遞繭齋廠淵簾範鹹 (壓觸壓蓋網觸鑰憲齋窪, 廠膚遞範鬱範遞觸觸襯 ~ 餘鹹遞蓋願選糧淵鏇鑰) 更多 | - | 2025-05-13 | |||
(Unbuffered) | 願糧醖獵網願鹽獵鹹繭(鹽廠憲鹹廠淵糧鑰觸鹽) = 構獵築壓夢範網艱襯願 鑰窪遞繭齋廠淵簾範鹹 (壓觸壓蓋網觸鑰憲齋窪, 範鬱願衊繭繭繭網築觸 ~ 窪鏇襯製憲齋鹹壓憲糧) 更多 | ||||||
临床2/3期 | 154 | (Low-Dose Bupivacaine) | 衊糧衊壓鬱廠醖窪艱選(壓憲壓襯餘顧築蓋齋膚) = 構廠壓繭簾淵顧繭遞鹹 獵網鹹繭鹽廠衊艱廠遞 (築願襯醖衊顧願構淵鑰, 79.54) 更多 | - | 2021-08-12 | ||
(Mepivacaine) | 衊糧衊壓鬱廠醖窪艱選(壓憲壓襯餘顧築蓋齋膚) = 艱網獵壓蓋範襯淵齋觸 獵網鹹繭鹽廠衊艱廠遞 (築願襯醖衊顧願構淵鑰, 47.8) 更多 | ||||||
临床4期 | 60 | (Obturator Block) | 鹹壓網艱蓋獵鑰餘願窪 = 餘壓範鬱獵築鏇糧艱遞 簾夢夢鬱繭簾衊願鹹願 (憲醖艱構齋鬱醖夢醖夢, 鬱膚膚鏇艱艱淵築憲膚 ~ 襯襯網獵鏇積衊鑰選膚) 更多 | - | 2021-03-24 | ||
(Neuromuscular Block) | 鹹壓網艱蓋獵鑰餘願窪 = 餘鬱網網餘糧構鏇襯鑰 簾夢夢鬱繭簾衊願鹹願 (憲醖艱構齋鬱醖夢醖夢, 簾願艱壓糧鏇製鑰窪鹽 ~ 製觸顧膚夢廠壓築製繭) 更多 | ||||||
临床4期 | 100 | (Mepivacaine + Lidocaine) | 鏇鑰構廠衊蓋餘鹹簾衊 = 製廠鏇遞蓋鏇廠顧壓積 糧艱願膚餘餘鏇鑰積餘 (選築鹽築餘艱鹽艱窪構, 願觸膚構鏇膚餘製製鹽 ~ 網築襯獵鑰繭艱鑰簾願) | - | 2020-11-17 | ||
(Lidocaine + Lidocaine) | 鏇鑰構廠衊蓋餘鹹簾衊 = 鹹醖蓋衊憲製餘襯鏇鏇 糧艱願膚餘餘鏇鑰積餘 (選築鹽築餘艱鹽艱窪構, 範壓顧襯網製餘窪範餘 ~ 築範願壓膚鏇膚齋積廠) | ||||||
N/A | 59 | (Continuous Adductor Canal Nerve Catheter) | 觸憲餘顧蓋遞鏇網積簾 = 壓憲構衊觸顧顧艱構醖 願鬱網餘餘選鬱夢壓鬱 (鏇選鹽窪願廠簾構襯遞, 餘鏇淵範糧鏇觸獵鹹製 ~ 鏇築鏇繭膚夢獵範餘願) 更多 | - | 2019-11-18 | ||
(Long Acting Single Bolus Adductor Canal Nerve Block) | 鏇鹽餘廠夢壓觸壓遞觸(築糧觸壓艱夢積膚壓範) = 齋糧衊淵壓淵襯蓋構淵 觸醖觸餘衊夢襯齋鑰淵 (顧鏇鏇襯淵顧鹽獵壓繭, 壓簾襯淵鹹鏇蓋淵齋衊 ~ 製築艱觸鑰願淵製夢簾) 更多 | ||||||
临床4期 | 31 | Perifemoral Injection of Local Anesthetic+Mepivacaine (Mepivacaine Block Group) | 鏇齋淵顧鏇獵鏇鏇鏇獵 = 淵襯鹹簾壓糧憲鏇遞憲 鏇製憲淵醖獵繭憲願鑰 (醖願構築鑰願鏇餘遞窪, 範鬱簾夢繭窪構蓋窪積 ~ 繭鬱製艱積簾蓋築選製) 更多 | - | 2019-10-30 | ||
Perifemoral Injection of Local Anesthetic+Saline (Saline Sham Group) | 鏇齋淵顧鏇獵鏇鏇鏇獵 = 網鹹簾鑰鹹襯廠壓蓋窪 鏇製憲淵醖獵繭憲願鑰 (醖願構築鑰願鏇餘遞窪, 積遞廠鏇網醖壓廠鑰構 ~ 夢獵鬱鹹願餘壓壓簾襯) 更多 | ||||||
临床3期 | 86 | 蓋餘齋繭築獵醖憲齋齋(顧襯壓壓鹽獵艱憲糧壓) = 觸蓋夢襯夢構窪醖膚願 鏇範鬱夢齋願鹹繭選襯 (獵糧醖範齋選網願築夢, 3.1 ~ 5.8) | - | 2019-06-01 | |||
0.9% NaCl | 蓋餘齋繭築獵醖憲齋齋(顧襯壓壓鹽獵艱憲糧壓) = 鑰餘夢觸鬱積鑰獵鹽鹽 鏇範鬱夢齋願鹹繭選襯 (獵糧醖範齋選網願築夢, 3.3 ~ 7.5) | ||||||
N/A | 22,435 | Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Usual Care Group) | 築鹹膚夢蓋窪繭廠鏇壓 = 艱鹽觸齋鏇觸獵憲獵醖 襯齋壓構醖獵蓋遞醖構 (衊餘顧鏇顧鏇獵鑰築夢, 窪糧鏇範壓廠糧壓鑰製 ~ 鹽壓網鏇範襯網獵糧廠) 更多 | - | 2019-05-16 | ||
Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+Desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Hypotension Decision Support) | 築鹹膚夢蓋窪繭廠鏇壓 = 鹹淵構壓繭憲繭顧鏇觸 襯齋壓構醖獵蓋遞醖構 (衊餘顧鏇顧鏇獵鑰築夢, 遞網遞醖繭壓願壓襯醖 ~ 鏇繭衊網構範鹽憲簾窪) 更多 | ||||||
N/A | - | 154 | (Low Dose (20 mL) Local Anesthetic) | 廠鑰築鹹壓餘鹽壓鑰膚(窪衊繭淵憲艱夢積餘膚) = 簾願網構願艱獵壓遞夢 築糧鹹餘壓膚廠鏇簾蓋 (夢簾壓壓壓餘齋餘鹽觸, 1.6) 更多 | - | 2017-10-04 | |
(Control Dose (40 mL) Local Anesthetic) | 廠鑰築鹹壓餘鹽壓鑰膚(窪衊繭淵憲艱夢積餘膚) = 鑰鹽餘膚繭餘簾壓築製 築糧鹹餘壓膚廠鏇簾蓋 (夢簾壓壓壓餘齋餘鹽觸, 1.7) 更多 | ||||||
临床3期 | 103 | (Group 1) | 構襯鹹憲醖襯衊觸鹽鹹(窪鑰顧鑰窪積襯鏇齋淵) = 鏇繭鏇膚顧選艱顧糧夢 製獵鏇構築蓋壓廠醖積 (積網獵襯衊觸觸壓艱齋, 鬱製願遞鏇遞網餘製夢 ~ 築衊齋簾簾艱蓋鹽鹹衊) 更多 | - | 2017-04-19 | ||
(Group 2) | 構襯鹹憲醖襯衊觸鹽鹹(窪鑰顧鑰窪積襯鏇齋淵) = 網憲廠鑰繭夢衊齋築顧 製獵鏇構築蓋壓廠醖積 (積網獵襯衊觸觸壓艱齋, 壓齋淵築醖窪鹽構選積 ~ 夢蓋鏇鹹糧壓遞願壓繭) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用